Navigation Links
Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th
Date:11/6/2009

AURORA, Ontario, Nov. 6 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / Pink Sheets: HXBPF) today announced that John Docherty, president and chief operating officer, will present at Merriman Curhan Ford's 6th annual Investor Summit on November 10, 2009 at 4:00 PM at the Sofitel Hotel in New York City. Mr. Docherty will provide an overview of the Company's leading product development programs L-DOS47 and Topical Interferon Alpha-2b. The slide show portion of the presentation will be posted on the Company's website, www.helixbiopharma.com, on November 10th, 2009.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is listed on the TSX and FSE under the symbol "HBP" and on the OTCQX International Market under the symbol "HXBPF."

About Merriman Curhan Ford

Merriman Curhan Ford (Nasdaq: MERR) is a financial services firm focused on fast-growing companies and the institutions that invest in them. The company offers high-quality investment banking, equity research, institutional services and corporate & venture services, and specializes in five growth industry sectors: CleanTech, Consumer, Media & Internet, Health Care, Natural Resources and Technology. For more information, please go to www.mcfco.com.

    For further information contact:
    Investor Relations
    Robert Flamm, Ph.D.
    Russo Partners LLC
    Tel: (212) 845-4226
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AlphaHelix Presents AmpXpress(TM) at the BIOTECHNICA Show
2. Helix BioPharma Closes Private Placement
3. Helix BioPharma Announces $13.5 Million Private Placement
4. Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
5. Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses
6. New and Updated Online Tutorials for dbGaP, GAD, and DGV from OpenHelix
7. Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
8. Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
9. Helix BioPharma to Present at the BioFinance 2009 Conference
10. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
11. Helix BioPharma Announces Q2 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , "The interface is the device," Nobel laureate ... properties to be found at the junctures where ... world of nanotechnology, the interfaces between layers of ... in such high-tech favorites as spintronics, high-temperature superconductors, ...
(Date:1/15/2014)... Jan. 15, 2014   Niagara Thermal Products is ... Buffalo BioBlower Technologies LLC ("B3") as the critical thermal ... award from the Army Corps of Engineers.  B3 has ... all biological contaminants and destroys VOCs and other chemical ...
(Date:1/15/2014)... and SAN JOSE, California , ... biotechnology company developing antibody-drug conjugates for cancer, today announced the ... of Directors. Dr Reynolds has over 20 years, development experience ... Officer at Seattle Genetics. "I am delighted to ...
(Date:1/15/2014)... A study has been launched to test whether technology ... help to tackle the problem of obesity.  This unique healthcare ... based in Stowmarket) and academics at University Campus Suffolk is ... which is inspired by equipment used to collect data about ...
Breaking Biology Technology:A deeper look at interfaces 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... , , , BRISBANE, ... results from operations for the second quarter and six months ended June 30, ... of 2009 of $36.7 million, or $0.81 per share, compared with a net ... 2008. , , Dan Welch, Chairman, Chief Executive ...
... ... Improved Website. The New Site Provides Users With A Comprehensive Overview Of Pace Analytical ... Also Offers An Expanded Service Description For Each Of Its Three Major Business Divisions: ... ...
... , REDWOOD CITY, Calif., Aug. ... antibody therapeutics that target cancer stem cells, today announced the ... potent anti-cancer activity in colon and breast cancer models for ... of targeting cancer stem cells to treat solid tumors. ...
Cached Biology Technology:InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 2InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 3InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 4InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 5InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 6InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 7InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 8InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 9InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 10InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 11InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 12InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 14InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 15One of the Nation's Leading Analytical Testing Laboratories is Now Easier to Access -- Pace Analytical Launches New Web Site to Showcase Its Three Business Divisions 2Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody 2Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody 3Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody 4
(Date:4/24/2014)... very pleased to announce that it has assumed ownership ... the University of Wisconsin. , The Journal ... peer-reviewed journal that publishes papers on all aspects of ... the molecular to the ecological -- as well as ... to individuals and institutions, and it provides a reasonably ...
(Date:4/24/2014)... by fungus could now be treated in three days, rather ... scientists. , Cryptococcus a form of yeast ... medical research. They are found in many parts of ... mainly affect people with weakened immune systems. This infection kills ... team has tested the effects of the most commonly used ...
(Date:4/24/2014)... Carolina State University and the University of North Carolina ... that could help identify arterial plaque that is at ... or stroke. , At issue is the plaque that ... of plaque are deemed "vulnerable," meaning that they are ... cause heart attack or stroke. , "Existing state-of-the-art technologies ...
Breaking Biology News(10 mins):ESA to publish the Journal of Insect Science 2Treatment for deadly yeast disease reduced to 3 days 2New ultrasound device may add in detecting risk for heart attack, stroke 2
... A team of researchers at the University of ... boardroom in an effort to build a business based ... The work of Claus Tittiger, professor of ... a highly competitive and intense National Science Foundation business-validation ...
... years of research at the Institute of Food Research, ... by food and drug companies worldwide. , IFR and ... secured funding from the Biotechnology and Biological Sciences Research ... to validate and improve how well it simulates the ...
... Pompeu Fabra University (Spain) have created a high resolution atlas ... The study demonstrates that an average image of an organ ... of comparing individual cases and differentiating healthy forms from pathologies. ... heart and its components such as the ventricles and ...
Cached Biology News:Insect research heads down path to start-up company with NSF I-Corps program 2Insect research heads down path to start-up company with NSF I-Corps program 3Commercial future for Model Gut 2An atlas of the human heart is drawn using statistics 2
... polypeptide hormones which belong to the ... TGF- superfamily is a large group ... many aspects of development, reproductive function ... incude TGF-s, bone morphogenetic proteins, growth ...
... EZ-Spread Plating Beads Sterile plating ... for glass rods and potentially hazardous ethanol flaming, ... Two choices of ready-to-use sterile packaging: dispenser bottle ... 50 plating, Fastest and easiest way ...
The new Silencer siRNA Starter Kit is perfect for researchers new to RNAi. It provides all of the reagents, protocols, and instructions necessary to get underway with siRNA transfection and ensure su...
... in a regulated environment, Pipette Tracker ... software that automates gravimetric pipette calibration ... that meets todays regulatory compliance requirements. ... solution that includes a full security ...
Biology Products: